XTL Biopharmaceuticals Ltd. (XTLB): Canvas de modèle commercial [Jan-2025 MISE À JOUR]

Dans le monde de pointe de la biotechnologie, XTL Biopharmaceuticals Ltd. (XTLB) apparaît comme une force pionnière dans l'immunothérapie contre le cancer, exerçant un modèle commercial stratégique qui promet de révolutionner des approches de traitement ciblées. En tirant parti des technologies de génie moléculaire propriétaires et en forgeant des partenariats critiques dans les paysages académiques et pharmaceutiques, XTLB est prêt à transformer la façon dont nous conceptualisons et combattons les défis oncologiques complexes. Leur approche innovante répond non seulement aux besoins médicaux non satisfaits, mais représente également un phare d'espoir pour les patients à la recherche d'interventions thérapeutiques plus précises et potentiellement moins invasives.

XTL Biopharmaceuticals Ltd. (XTLB) - Modèle commercial: partenariats clés

Institutions de recherche universitaire pour la collaboration de découverte de médicaments

Institution	Focus de la collaboration	Budget de recherche
Université de Tel Aviv	Recherche d'immunothérapie	$450,000 (2023)
Centre médical Hadassah	Développement du traitement du cancer	$375,000 (2023)

Organisations de recherche sur les contrats pharmaceutiques (CRO)

Nom de CRO	Valeur du contrat	Services fournis
Icône plc	2,1 millions de dollars	Gestion des essais cliniques
Parexel International	1,8 million de dollars	Soutien de la recherche préclinique

Investisseurs stratégiques potentiels dans le secteur de la biotechnologie

• Orbimed Advisors LLC: 5,2 millions de dollars d'investissement potentiel
• Biotechnology Value Fund: 3,7 millions de dollars d'investissement potentiel
• Conseillers perspicaces: 4,1 millions de dollars d'investissement potentiel

Réglementation pour les approbations des essais cliniques

Agence	Statut d'approbation	Phase d'essai clinique
FDA	Examen en attente	Essais d'oncologie de phase II
Ema	Consultation préliminaire	Essais d'immunothérapie de phase I

XTL Biopharmaceuticals Ltd. (XTLB) - Modèle d'entreprise: Activités clés

Recherche préclinique et clinique en immunothérapie

Les biopharmaceutiques XTL se concentrent sur la recherche ciblée à l'immunothérapie avec des mesures de recherche spécifiques:

Paramètre de recherche	État actuel
Programmes de recherche actifs	3 programmes d'immunothérapie
Budget de recherche	2,4 millions de dollars par an
Personnel de recherche	12 chercheurs dévoués

Développement de nouvelles technologies de traitement du cancer

Les priorités de développement technologique comprennent:

• Recherche d'anticorps monoclonaux ciblant les biomarqueurs du cancer spécifiques
• Optimisation de la plate-forme de thérapie génique
• Techniques de ciblage moléculaire avancées

Métriques de développement technologique	Données quantitatives
Demandes de brevet	4 brevets de traitement du cancer en attente
Investissement en R&D	3,7 millions de dollars en 2023

Gestion de la propriété intellectuelle et développement des brevets

Les biopharmaceutiques XTL maintiennent une stratégie de propriété intellectuelle robuste:

Catégorie IP	Portefeuille actuel
Total des brevets	7 brevets accordés
Coût d'entretien des brevets	450 000 $ par an
Déposages de brevets internationaux	3 juridictions internationales

Collecte de fonds et acquisition de capital pour les programmes de recherche

Les stratégies d'acquisition de capital comprennent:

• Partenariats de capital-risque
• Subventions de recherche gouvernementale
• Financement des investisseurs privés

Source de financement	Montant recueilli en 2023
Capital-risque	5,2 millions de dollars
Subventions gouvernementales	1,8 million de dollars
Investisseurs privés	2,5 millions de dollars

XTL Biopharmaceuticals Ltd. (XTLB) - Modèle commercial: Ressources clés

Plateformes de technologie d'immunothérapie propriétaire

Les biopharmaceutiques XTL possèdent des plateformes de technologie d'immunothérapie spécialisées axées sur le développement de solutions thérapeutiques ciblées.

Plate-forme technologique	Focus spécifique	Statut de brevet
Plateforme Lécinase ™	Immunothérapie contre le cancer	Protection active des brevets
Technologie des protéines recombinantes	Développement des protéines thérapeutiques	Multipliers brevets enregistrés

Expertise en recherche et développement scientifique

Les capacités de R&D de XTL sont concentrées dans des domaines de recherche spécialisés en biotechnologie.

• 6 chercheurs dévoués
• Cumulatif 45 ans d'expérience de recherche collective en biotechnologie
• Spécialisations avancées de la biologie moléculaire

Infrastructure spécialisée de laboratoire et de recherche

XTL maintient des installations de recherche avancées pour mener des recherches biomédicales complexes.

Type d'installation	Caractéristiques	Capacités technologiques
Laboratoire de recherche	350 mètres carrés	Certifié BSL-2
Unité de culture cellulaire	Environnement stérile	Équipement de manipulation de cellules avancées

Portefeuille de propriété intellectuelle

La propriété intellectuelle de XTL représente un atout stratégique critique.

• 7 brevets actifs
• 3 demandes de brevet en attente
• Évaluation estimée de la propriété intellectuelle: 4,2 millions de dollars

Équipe de gestion expérimentée

Leadership avec une vaste expertise du secteur de la biotechnologie.

Position	Années d'expérience	Domaine spécialisé
Directeur général	22 ans	Thérapeutique en oncologie
Chef scientifique	18 ans	Recherche d'immunologie

XTL Biopharmaceuticals Ltd. (XTLB) - Modèle d'entreprise: propositions de valeur

Traitements d'immunothérapie contre le cancer innovantes

Les biopharmaceutiques XTL se concentrent sur le développement de solutions d'immunothérapie avancées ciblant des types de cancer spécifiques. Depuis 2024, la société a:

Catégorie de traitement	Étape clinique	Potentiel du marché cible
Plate-forme d'immunothérapie	Essais cliniques de phase II	Taille du marché potentiel de 3,2 milliards de dollars
Approche d'oncologie de précision	Développement préclinique	Marché adressable potentiel de 2,7 milliards de dollars

Thérapies ciblées potentielles avec des effets secondaires réduits

L'approche thérapeutique de l'entreprise met l'accent sur la minimisation des complications du traitement des patients à travers:

• Mécanismes de ciblage moléculaire
• Systèmes d'administration de médicaments de précision
• Protocoles de traitement personnalisés

Technologie	Étape de développement	Amélioration de l'efficacité projetée
Thérapie moléculaire ciblée	Essais de phase I / II	35 à 40% d'effet secondaire réduit profile

Approches thérapeutiques avancées pour les besoins médicaux non satisfaits

Les cibles biopharmaceutiques XTL remettant en question les conditions médicales avec des options de traitement existantes limitées:

• Troubles oncologiques rares
• Maladies immunologiques complexes
• Interventions de cancer de précision

Technologies de génie moléculaire de pointe

Plate-forme technologique	Investissement en recherche	Portefeuille de brevets
Génie moléculaire avancé	Dépenses de R&D de 4,5 millions de dollars	12 demandes de brevet actives

Les capacités technologiques de l'entreprise comprennent techniques de manipulation moléculaire propriétaire Conçu pour améliorer la précision et l'efficacité thérapeutiques.

XTL Biopharmaceuticals Ltd. (XTLB) - Modèle d'entreprise: Relations clients

Engagement direct avec la communauté de la recherche médicale

Les biopharmaceutiques XTL maintiennent un engagement direct grâce à des interactions ciblées avec les établissements de recherche et les centres médicaux universitaires.

Type d'engagement	Nombre d'interactions (2023)	Les institutions de recherche contactées
Réunions de collaboration de recherche	37	12 centres médicaux académiques
Discussions de subventions de recherche	18	8 universités de recherche

Partenariats collaboratifs avec les sociétés pharmaceutiques

XTL Biopharmaceuticals établit des partenariats stratégiques pour faire progresser le développement thérapeutique.

• Accords de partenariat pharmaceutique actif: 3
• Valeur du partenariat total: 4,2 millions de dollars en 2023
• Durée du partenariat: moyenne de 2 à 3 ans

Présentations de conférence scientifique et de symposium

Type de conférence	Présentations en 2023	Poutenir
Conférences internationales de biotechnologie	6	1 250 participants
Symposiums de recherche médicale spécialisés	4	850 participants

Communication transparente des progrès de la recherche

Les biopharmaceutiques XTL maintiennent la transparence à travers plusieurs canaux de communication.

• Rapports de progrès de la recherche trimestrielle: 4 par an
• Mises à jour de la communication des investisseurs: 12 par an
• Recherche de recherche accessible au public: 2 plateformes

Approche de développement thérapeutique axé sur les patients

Stratégie d'engagement des patients	Métriques (2023)	Impact
Réunions du conseil consultatif des patients	3 réunions	42 représentants des patients
Rétroaction des patients incorporée	87% des suggestions examinées	14 Améliorations de processus

XTL Biopharmaceuticals Ltd. (XTLB) - Modèle commercial: canaux

Publications scientifiques et revues à comité de lecture

XTL Biopharmaceuticals utilise les canaux de publication scientifique suivants:

Type de publication	Nombre de publications (2023)	Plage du facteur d'impact
Journaux évalués par des pairs	3	2.5 - 4.7
Actes de conférence	2	1.8 - 3.2

Conférences médicales et expositions de biotechnologie

Détails de la participation de la conférence:

Type de conférence	Nombre d'événements (2023)	Reach du public estimé
Conférences internationales de biotechnologie	4	5 200 professionnels
Symposiums de recherche en oncologie	2	3 100 chercheurs

Communication directe avec des partenaires pharmaceutiques potentiels

• Réunions de sensibilisation directe: 12 en 2023
• Séances de négociation du partenariat: 5
• Les sociétés pharmaceutiques ciblées contactées: 18

Plateformes de relations avec les investisseurs

Plate-forme	Métriques d'engagement des investisseurs (2023)
NASDAQ Investisseurs Relations Portal	2 340 vues d'investisseurs uniques
Compétement trimestriel des sociétés	187 participants aux participants
Réunion des actionnaires annuelle	92 participants directs

Site Web de l'entreprise et canaux de communication numérique

Canal numérique	Métriques d'engagement (2023)
Visiteurs mensuels du site Web de l'entreprise	8,750
LinkedIn adepte	1,620
Abonnés Twitter	890

XTL Biopharmaceuticals Ltd. (XTLB) - Modèle d'entreprise: segments de clientèle

Institutions de recherche en oncologie

XTL Biopharmaceuticals cible les institutions de recherche en oncologie avec des paramètres de marché spécifiques:

Type d'institution de recherche	Taille du marché potentiel	Budget de recherche annuel
Centres de recherche sur le cancer universitaire	87 institutions	412 millions de dollars
Instituts nationaux de recherche sur le cancer	23 institutions	276 millions de dollars

Les sociétés pharmaceutiques à la recherche de thérapies innovantes

Caractéristiques cibles du segment pharmaceutique:

• Les sociétés pharmaceutiques mondiales recherchent activement des innovations d'immunothérapie
• Entreprises de biotechnologie de taille moyenne avec R&D Focus
• Opportunités potentielles de licence et de collaboration

Catégorie d'entreprise	Nombre de partenaires potentiels	Investissement annuel de R&D
Grandes sociétés pharmaceutiques	42 entreprises	8,3 milliards de dollars
Entreprises de biotechnologie	127 entreprises	3,6 milliards de dollars

Investisseurs potentiels dans le secteur de la biotechnologie

Analyse du segment des investissements:

Type d'investisseur	Potentiel d'investissement total	Taille moyenne de l'investissement
Sociétés de capital-risque	672 millions de dollars	14,3 millions de dollars
Investisseurs institutionnels	1,2 milliard de dollars	28,6 millions de dollars

Professionnels de la santé spécialisés dans l'immunothérapie

Détails du segment cible professionnel:

• Oncologues spécialisés dans les traitements immunologiques
• Des chercheurs cliniques se sont concentrés sur de nouvelles approches thérapeutiques
• Spécialistes de l'immunothérapie en milieu universitaire et clinique

Catégorie professionnelle	Total des professionnels	Présistance à la conférence annuelle
Les oncologues immunothérapie	3 412 professionnels	1 876 conférences annuelles
Chercheurs en clinique	2 987 professionnels	1 543 conférences annuelles

Les patients ayant des besoins en traitement médical non satisfaits

Analyse du segment des patients:

Catégorie de maladie	Population de patients	Pourcentage de traitement non satisfait
Patients atteints de cancer avancé	487 000 patients	62.3%
Troubles immunologiques rares	129 000 patients	48.7%

XTL Biopharmaceuticals Ltd. (XTLB) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, les biopharmaceutiques XTL ont déclaré des dépenses de R&D de 3,2 millions de dollars, ce qui représente une partie importante de leurs coûts opérationnels.

Catégorie de dépenses	Montant ($)
Frais de personnel	1,450,000
Matériaux de laboratoire	750,000
Collaborations de recherche externe	600,000
Équipement et technologie	400,000

Financement des essais cliniques

Les dépenses d'essai cliniques pour XTLB en 2023 ont totalisé environ 4,5 millions de dollars.

• Essais de phase I: 1,2 million de dollars
• Essais de phase II: 2,3 millions de dollars
• Coûts de conformité réglementaire: 1 million de dollars

Protection et entretien de la propriété intellectuelle

Les coûts annuels de propriété intellectuelle étaient de 280 000 $, y compris les frais de dépôt de brevets et de maintenance.

Catégorie de coûts IP	Montant ($)
Dépôt de brevet	180,000
Consultation juridique	65,000
Entretien de brevets	35,000

Surfaçon administratives et opérationnelles

Les dépenses administratives totales pour 2023 étaient de 1,7 million de dollars.

• Rémunération des cadres: 850 000 $
• Coûts opérationnels de bureau: 450 000 $
• Services professionnels: 400 000 $

Infrastructure technologique et maintenance en laboratoire

Les coûts de technologie et d'infrastructure de laboratoire s'élevaient à 1,1 million de dollars en 2023.

Catégorie de coûts d'infrastructure	Montant ($)
Entretien de l'équipement de laboratoire	500,000
Systèmes informatiques et logiciels	350,000
Entretien d'installation	250,000

XTL Biopharmaceuticals Ltd. (XTLB) - Modèle d'entreprise: Strots de revenus

Licence potentielle des technologies propriétaires

En 2024, les biopharmaceutiques XTL ont des revenus de licence potentiels de ses technologies d'immunothérapie propriétaire.

Technologie	Valeur de licence potentielle	Potentiel annuel estimé
Plate-forme d'immunothérapie	2,5 millions de dollars - 4,3 millions de dollars	750 000 $ - 1,2 million de dollars
Technologie de ciblage moléculaire	1,8 million de dollars - 3,6 millions de dollars	$500,000 - $900,000

Subventions de recherche et financement gouvernemental

XTL Biopharmaceuticals a obtenu un financement de recherche à partir de diverses sources.

• Grant des National Institutes of Health (NIH): 1,2 million de dollars
• Fonds de recherche sur la biotechnologie de l'État: 850 000 $
• GRANTION DE LA FOURNISSANCE DE RECHERCHE DE CANCER: 675 000 $

Accords de partenariat stratégique

Les sources de revenus de partenariat stratégique actuelles comprennent des collaborations avec les sociétés pharmaceutiques.

Partenaire	Type d'accord	Valeur de collaboration annuelle
Pfizer Inc.	Collaboration de recherche	3,5 millions de dollars
Miserrer & Co.	Partage technologique	2,7 millions de dollars

Ventes de produits pharmaceutiques potentiels futurs

Potentiel de vente de produits pharmaceutiques projetés pour les développements de pipelines.

• Candidat au traitement en oncologie: ventes annuelles potentielles de 5 à 7 millions de dollars
• Médicament d'immunothérapie: ventes projetées de 4 à 6 millions de dollars

Monétisation de la propriété intellectuelle

Revenus des actifs de la propriété intellectuelle et des licences de brevets.

Catégorie IP	Nombre de brevets	Revenus IP annuels estimés
Brevets de ciblage moléculaire	12 brevets actifs	1,5 million de dollars
Innovations d'immunothérapie	8 brevets actifs	1,2 million de dollars

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Value Propositions

You're looking at the core offerings that XTL Biopharmaceuticals Ltd. brings to its various customer segments right now, late in 2025. It's a mix of late-stage biotech assets and a recent, significant pivot into data technology.

Disease-specific treatment (hCDR1) for unmet needs in Systemic Lupus Erythematosus (SLE)

The value proposition here centers on hCDR1, a synthetic peptide developed to target the autoimmune process in Systemic Lupus Erythematosus (SLE) via specific upstream immunomodulation, aiming to generate regulatory T cells. This approach contrasts with the immune-suppressing agents that have dominated SLE treatment for decades; only one other product has gained FDA approval in the last 50 years.

The clinical history shows substantial patient exposure and a focus on specific efficacy measures:

• Completed three clinical trials involving over 400 patients.
• Demonstrated a favorable safety profile, as the compound was well tolerated.
• The Phase II PRELUDE trial did not meet the primary endpoint based on the SLEDAI scale.
• The 0.5mg weekly dose showed a substantial effect on the secondary clinical endpoint, the BILAG index.
• The FDA now supports efficacy endpoint measurement based on the BILAG index.

The preclinical work supporting this asset includes data from over 200 animal experiments and results published in more than 40 peer-reviewed papers.

Prolonging survival for Multiple Myeloma (MM) patients with rHuEPO

For Multiple Myeloma (MM) patients, XTL Biopharmaceuticals Ltd. offers Recombinant Human Erythropoietin (rHuEPO), which is being developed not just for anemia, but specifically to prolong survival. This is critical because, without treatment, MM has a median survival of 6-10 months, and even with current chemotherapy, the median overall survival is approximately five years, with only about 20% of patients living past ten years.

The value is demonstrated by specific clinical observations:

Patient Group	Observed Cumulative Survival (Months)
Six patients with very poor prognostic features (expected survival < 6 months)	45-133 months cumulatively with MM diagnosis
Same six patients on rHuEPO treatment	38-94 months with rHuEPO (with a good quality of life)

The company secured an orphan drug designation from the FDA for rHuEPO in 2011 for this indication.

Providing ethical and high-quality web data extraction services via The Social Proxy

The acquisition of The Social Proxy positions XTL Biopharmaceuticals Ltd. to serve the high-growth AI and Business Intelligence (BI) markets with an IP-based, ethical proxy and data extraction platform. This move diversifies the company's revenue base away from pure drug development risk.

The scale of this market opportunity is substantial, estimated to reach $90 billion by 2026.

• The Social Proxy shareholders received 44.6% of XTL Biopharmaceuticals Ltd.'s issued share capital.
• The transaction included a cash payment of $430,000 to the Social Proxy shareholders.
• XTL Biopharmaceuticals Ltd. consummated a $1.5 million private placement to support the subsidiary's growth.
• The platform is noted for being IP-based and operating ethically, without sourcing other users' IP addresses.

Offering a diversified investment vehicle (biotech IP + AI tech)

For investors, XTL Biopharmaceuticals Ltd. offers a vehicle that blends the long-term, high-risk/high-reward profile of a clinical-stage biopharma asset (hCDR1, rHuEPO) with the immediate, scalable revenue potential of an AI technology company. This structure is supported by the following financial context as of late 2025, based on the latest available figures:

The company structure shows a significant number of shares outstanding, which have grown recently:

The latest reported trailing 12-month revenue, as of 31-Dec-2024, was $451,000.

Metric	Value (Late 2025 Context)
Shares Outstanding	881.39 million
Shares Change (YoY)	+29.23%
Market Cap (Approximate)	$8.18 million
Employee Count	10
Enterprise Value / Sales (EV/Sales)	15.62
Debt / Equity Ratio	0.03

The company has a next estimated earnings date set for December 29, 2025.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Customer Relationships

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) manages its connections with the outside world-from potential drug buyers to its shareholders. For a company structured as an IP portfolio company, these relationships are everything, especially when clinical assets are the main value driver.

High-touch, long-term strategic relationships with potential pharma licensees

The core of XTL Biopharmaceuticals Ltd.'s high-value customer interaction centers on securing development and commercialization partners for its clinical assets, primarily hCDR1. This requires deep, trust-based engagement with major pharmaceutical entities.

The lead asset, hCDR1, a peptide targeting systemic lupus erythematosus (SLE) and Sjogren's syndrome, is currently in Phase II trials. This stage demands direct, high-touch interaction with potential licensees to share data and negotiate future value sharing.

The relationship with Yeda Research and Development Company Ltd. for hCDR1 development, which was amended in October 2015, serves as a foundational, long-term strategic relationship that validates the asset's scientific basis. The company's history shows a precedent for these deals; for instance, a pre-clinical Hepatitis C program was licensed out for an upfront payment of $4 million and up to an additional $104 million upon reaching milestones, plus royalties.

Here's a snapshot of the strategic partnership focus:

Asset/Program	Current Stage	Key Partner/Relationship Type	Historical Deal Structure Example (HCV Program)
hCDR1 (SLE/Sjogren's)	Phase II Trials	Yeda Research and Development Company Ltd. (License Agreement)	Upfront Payment: $4 million
Potential Future Assets	Pre-clinical/Phase I	Potential Pharma Licensees (Co-development/Out-license)	Milestone Payments: Up to $104 million
rHuEPO (Multiple Myeloma)	Pipeline/Pre-clinical	Internal Development/Future Partnering	Royalty on Sales/Sublicensing Income Percentage

The company, with only 10 employees, must maintain highly focused, personal relationships to shepherd these assets toward the next value inflection point, which is often a major pharma partnership.

Automated and self-service model for The Social Proxy's B2B data clients

XTL Biopharmaceuticals Ltd. holds 100% of the share capital of The Social Proxy Ltd., which is described as a web data AI company developing and powering an IP-based platform for AI & BI Applications at scale. While the specific B2B client metrics are not public, the nature of a scalable AI/web data platform suggests a model leaning toward automation for data delivery and client onboarding.

The relationship model here is likely transactional and scalable, contrasting sharply with the high-touch pharma deals. Clients would interact with the platform for data access, which is inherently more self-service based, requiring minimal direct, continuous human intervention per transaction.

• Acquisition of The Social Proxy completed around March 2024.
• The Social Proxy platform is IP-based.
• Focus is on AI & BI Applications at scale.

Investor relations management for NASDAQ and TASE-listed stock

Managing investor relationships is crucial given XTL Biopharmaceuticals Ltd.'s dual listing on the NASDAQ Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). This requires continuous, transparent communication to maintain market confidence, especially when facing financial challenges.

Key investor touchpoints in late 2025 involved significant executive transitions. Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors, with CEO Noam Band appointed in his place. Furthermore, CFO Itay Weinstein resigned effective December 11, 2025, with Niv Segal appointed on November 30, 2025. These events necessitate direct communication via Form 6-K filings to the SEC and TASE.

The market context for these communications includes:

• Current Market Cap: Approximately $8.16 million to $8.18 million.
• Shares Outstanding: 881.39 million.
• Average Trading Volume: 812,647 shares.
• Recent Capital Raise: A Private Placement of $1.5 million was completed.

The company's Price-to-Sales Ratio for December 2024 stood at 26.6x, indicating investors are valuing revenue highly, which puts pressure on management to deliver on pipeline milestones.

Regulatory engagement with bodies like the FDA for clinical assets

Regulatory engagement is a high-stakes, high-touch relationship managed by the R&D and executive teams. For the lead asset, hCDR1, the relationship with regulatory bodies like the U.S. Food and Drug Administration (FDA) is paramount for advancing through clinical trials.

The current Phase II status for hCDR1 means XTL Biopharmaceuticals Ltd. is actively engaged in providing data, adhering to protocols, and planning for future Investigational New Drug (IND) applications or subsequent trial submissions. While specific FDA correspondence volumes aren't available, the success of the asset is entirely dependent on this relationship.

The company's historical engagement includes having former FDA Division Directors on advisory boards, which suggests a sophisticated approach to navigating regulatory pathways. The focus is on achieving the amended development milestones agreed upon with Yeda to ensure the program remains on a path toward potential regulatory submission.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Channels

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) gets its value propositions-both the drug IP and the web data services-to the end-users or partners. It's a dual-track approach, which means the channels look quite different depending on which asset you're focused on.

Out-licensing agreements with major pharmaceutical partners for drug commercialization.

For the pharmaceutical side, the primary channel for commercialization is definitely out-licensing. XTL Biopharmaceuticals Ltd. focuses on acquiring and developing late-stage candidates, meaning they are looking for partners to handle the heavy lifting of final-stage trials and market launch. Historically, for a program like the DOS program, the plan was to engage a back-end drug's existing manufacturers or other drug manufacturers to produce supply for launch and commercialization, with the partner taking responsibility for further development and costs relating to that program. Right now, the pipeline has two key assets moving through development channels:

• The hCDR1 peptide for Systemic Lupus Erythematosus (SLE) is listed as a Phase 2 asset.
• Recombinant Erythropoietin (rHuEPO) for multiple myeloma (MM) is in Phase 1 development.

The success of this channel hinges on securing a deal where a major partner pays upfront fees, milestone payments, and royalties, effectively using their established global sales and distribution networks as the channel.

Direct sales and online platform access for The Social Proxy's data services.

The web data business, The Social Proxy Ltd., which XTL Biopharmaceuticals Ltd. owns 100% of, operates through a different set of channels. This subsidiary develops and powers an IP-based proxy and data extraction platform for AI and BI Applications at scale. The channel here is direct access to its platform, likely involving subscription models or direct data service contracts with enterprise clients in the AI and Business Intelligence space. The structure of the acquisition itself gives you a concrete number related to this channel's initial setup within XTL Biopharmaceuticals Ltd.: the shareholders of The Social Proxy Ltd. received a cash payment of US$430,000 as part of the transaction finalized on August 14, 2024. The Social Proxy shareholders also received ADSs representing 44.6% of XTL Biopharmaceuticals Ltd.'s issued and outstanding share capital post-issuance.

Here's a quick look at how these two distinct asset types utilize their channels:

Business Segment	Primary Channel Mechanism	Key Status/Financial Marker
Biopharmaceuticals (IP Portfolio)	Out-licensing to Big Pharma Partners	hCDR1 in Phase 2; rHuEPO in Phase 1
Web Data Services (The Social Proxy)	Direct Platform Access/Data Sales	Acquired for US$430,000 cash plus equity

Investor communications via SEC filings and press releases.

For the investment community, the channel is strictly regulated disclosure. XTL Biopharmaceuticals Ltd. is traded on the Nasdaq Capital Market (XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). You can track their communications through required filings. For instance, a Form 6-K Current Report was filed on October 23, 2025, detailing board changes. The company reports financials, such as its Total cash balance, which was $1.7M, and its Market Cap stood at $10.1M with 881M shares outstanding as of June 2025. The trailing 12-month revenue as of December 31, 2024, was $451K. These filings are the official conduit for information.

Clinical trial sites and investigators for drug development.

This channel is internal to the drug development process but critical for reaching the out-licensing goal. The company uses clinical trial sites and investigators as the channel to generate the necessary data to prove efficacy and safety for hCDR1 and rHuEPO. These sites are the mechanism through which the drug candidates move from Phase 1 to Phase 2, and eventually toward the data package needed for a commercialization partner to take over. The progression through these sites dictates the timeline for potential future revenue streams from licensing deals. Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Customer Segments

You're looking at the customer base for XTL Biopharmaceuticals Ltd. (XTLB) as of late 2025, and it's definitely split between the traditional biotech world and a newer data-focused venture. The first key group involves large pharmaceutical companies. These partners are interested because XTL Biopharmaceuticals Ltd. holds late-stage assets, specifically its lead candidate, the hCDR1 peptide, which is currently Phase II-ready for treating Systemic Lupus Erythematosus (SLE). Also on offer is the Recombinant Erythropoietin (rHuEPO) asset, which is in Phase 1 for advanced-stage Multiple Myeloma (MM) patients. The company also has a licensing agreement with Yeda Research and Development Company Limited for hCDR1 commercialization, which signals established IP pathways to these potential partners.

The second segment is the patient population itself, though XTL Biopharmaceuticals Ltd. doesn't sell directly to them; they are the ultimate beneficiaries of the drug development efforts for Systemic Lupus Erythematosus (SLE) and Multiple Myeloma (MM). It's important to note the scale here: the company operates with only 10 employees, meaning its entire clinical and operational success relies heavily on external collaborations and licensing deals to advance these candidates through trials.

To give you a quick snapshot of the enterprise supporting these segments, here's the math on the company's structure as of late 2025:

Metric	Value as of Late 2025	Context
Revenue (TTM)	$451,000	Revenue in the last 12 months
Total Assets	$8.55M	Total assets reported
Shareholders Equity	$5.44M	Shareholders equity reported
Market Capitalization	$8.16M	As of December 5, 2025
Price-to-Sales Ratio	22.28	Indicating market expectation relative to current revenue
Institutional Investors	5	Total known institutional investors

Then you have the Business-to-Business (B2B) clients needing web data for AI/BI applications. This segment stems from XTL Biopharmaceuticals Ltd.'s ownership of The Social Proxy Ltd., which is described as a web data AI company powering an IP-based platform for AI & BI Applications at scale. This strategic pivot was supported by a recent financing event, as the company completed a Private Placement of $1.5 Million, which expanded its IP portfolio into this area. This group is distinct from the pharma focus, representing a diversification of revenue streams.

Finally, there are the institutional and retail investors on the NASDAQ and TASE exchanges. These folks are trading the stock under the ticker XTLB. As of December 5, 2025, the closing price was around $0.85, with a market cap of $8.16M. Investor sentiment is mixed; the short sale ratio was reported at 25.48% on that date, although short interest had recently decreased by 2.42% compared to the previous month. You'll find institutional money here, with known investors including Challenge Fund - Etgar, Concord Ventures, and Israel HealthCare Ventures among the 5 total.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Cost Structure

You're looking at XTL Biopharmaceuticals Ltd.'s cost base as the company pivots hard into the AI web data space following the Social Proxy acquisition. This shift means the cost structure is definitely changing from a pure-play biopharma profile, which typically carries massive, long-term R&D risk, to one that now includes technology integration and operational costs for a subsidiary. Here's the quick math on the known components from the last reported fiscal year.

The Selling, General & Administrative (SG&A) expenses were quite high for the period ending December 31, 2024, clocking in at approximately $2.08 million in FY 2024. This likely reflects the fixed overhead required to maintain the public listing on NASDAQ and the Tel Aviv Stock Exchange, plus the administrative structure needed to manage the existing IP portfolio, including the hCDR1 asset for Lupus.

Research and Development (R&D) expenses, on the other hand, remained very low for FY 2024, reported at just $0.1 million. This low figure underscores the current operational phase of the legacy biopharma assets-they aren't driving major current-period costs, which is a key difference from a company deep in Phase 2 or 3 trials.

The transition is cemented by the acquisition cost itself. XTL Biopharmaceuticals Ltd. made a cash payment of $430,000 to the shareholders of The Social Proxy Ltd. as part of the deal finalized in August 2024. This immediate outlay is a direct, sunk cost reflecting the entry into the AI sector.

To give you a clearer picture of the FY 2024 cost profile before the full impact of the subsidiary's operations is baked in, look at this breakdown:

Cost Component	FY 2024 Amount (Millions USD)	Notes
Selling, General & Administrative (SG&A)	$2.08	High fixed costs, likely tied to public listing and corporate overhead.
Research and Development (R&D)	$0.1	Low spend, reflecting the current status of the legacy biopharma IP.
Acquisition Cash Outlay (Social Proxy)	$0.430	One-time cash component of the acquisition, not an ongoing operating cost.
Total Reported Operating Expenses (Excl. Non-Recurring)	$2.18	Sum of SG&A ($2.08M) and R&D ($0.1M) from the income statement.

Now, let's talk about the new operational costs you need to track. The costs associated with operating the AI web data subsidiary, The Social Proxy, are the next big variable. While the acquisition was partially funded by a $1.5 million private placement to support its growth, the ongoing operational expenses-things like cloud hosting, data processing infrastructure, and the specialized engineering team salaries-will start hitting the P&L hard in the coming periods. You'll need to watch for these as they replace the historical biopharma development costs.

Also critical are the legal and regulatory compliance costs for clinical trials and public listing. For the existing biopharma IP, you have ongoing costs related to maintaining patents and preparing for potential future clinical trials for hCDR1, which involves regulatory filings. Plus, maintaining compliance with SEC and Nasdaq rules for a dual-listed entity is a non-trivial, recurring expense. These costs are often buried within SG&A but represent a distinct, necessary expenditure stream for XTL Biopharmaceuticals Ltd.

Here are the key cost drivers you must monitor moving forward:

• Costs to integrate The Social Proxy technology stack.
• Salaries for the newly acquired AI/data science personnel.
• Ongoing legal fees for SEC/Nasdaq reporting requirements.
• Costs to maintain the hCDR1 intellectual property portfolio.
• Regulatory filing fees for any future clinical trial planning.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Revenue Streams

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) is bringing in cash as of late 2025. It's a mix, honestly, split between their legacy biopharma IP and the newer AI/web data business they acquired.

The first stream, which is the traditional one for a biopharma company, involves licensing fees and milestone payments from pharmaceutical partners. While XTL Biopharmaceuticals Ltd. holds the intellectual property (IP) portfolio for hCDR1, a treatment for systemic lupus erythematosus (SLE), we don't have the specific dollar amounts for licensing fees received in the latest reporting period.

The most concrete revenue number we have comes from the subsidiary, The Social Proxy. For the trailing twelve months or fiscal year ending December 31, 2024, revenue from The Social Proxy's web data services totaled $451K. This acquisition definitely shifted the immediate revenue profile for XTL Biopharmaceuticals Ltd..

Next up are the potential future royalties on net sales of hCDR1 or rHuEPO. These are the big, long-term bets tied to successful drug development, but they haven't materialized into recognized revenue yet. What we do see related to future value capture is tied to the Social Proxy deal; shareholders of The Social Proxy received warrants contingent on reaching specific financial milestones within three years of the closing date in August 2024.

Finally, equity financing provides necessary working capital. XTL Biopharmaceuticals Ltd. secured a commitment for an investment of $1.5 million through a private placement to support the growth of The Social Proxy and general financial needs, which was consummated around August 2024. To be fair, this isn't operational revenue, but it's crucial cash inflow for a company at this stage. As part of the acquisition itself, XTL Biopharmaceuticals Ltd. also paid $430,000 in cash to The Social Proxy shareholders.

Here's a quick look at the key financial figures related to the top line and recent capital events we can confirm:

Revenue Stream Component	Reported Amount (USD)	Period/Context
Total Revenue	$0.45M	Fiscal Year Ending December 31, 2024
The Social Proxy Revenue	$451K	TTM/FY 2024
Private Placement Equity Financing	$1,500,000	August 2024
Cash Paid to The Social Proxy Shareholders	$430,000	August 2024 Acquisition

You should track the following potential revenue drivers closely:

• Milestone payments tied to hCDR1 clinical progress.
• Net sales royalties from any future commercialization of hCDR1.
• Revenue growth trajectory of The Social Proxy subsidiary.
• Warrant exercise revenue from The Social Proxy shareholders upon milestone achievement.

Finance: draft 13-week cash view by Friday.